Is Vaxart Inc (NASDAQ:VXRT) A Buy Or Sell After The Recent Jump?

Clinical trials for Vaxart Inc (NASDAQ:VXRT) oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier  (8.21)

Vaxart has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier.

“These results are very important because they support our belief that our oral tablet vaccines have the potential to be used repeatedly for indications that may require an annual boost, such as flu, COVID-19, or norovirus,” said Andrei Floroiu, Vaxart’s Chief Executive Officer. “We are excited by these findings and by the implications for all of our vaccines.”

Key metrics identified in the boosting study were as follows:

Serum antibody blocking titer 50, a surrogate neutralizing antibody measurement, increased in both previously vaccinated and unvaccinated subjects by similar amounts.

Antibody secreting B cell (ASC) responses to norovirus VP1 measured seven days post-boost were no different than those in subjects receiving the vaccine for the first time.

Serum IgG and IgA antibody responses were significantly elevated 29 days post-boost immunization, with no difference in titer between subjects that had received a prior oral norovirus vaccine and those who had not previously been vaccinated.